Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Nov 1, 2017
-- Ended third quarter with a strong cash position of $423M -- CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the third quarter ended September 30, 2017 and provided a corporate update. "We continue to believe in the potential for the approval and laun...
Nov 1, 2017
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in the Phase 1 study to compare th...
Oct 18, 2017
CAMBRIDGE, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S. financial markets open on Wednesday, November 1, 2017.    ...
Oct 2, 2017
CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the promotion of Dr. Ganesh Kaundinya to Chief Operating Officer. Dr. Kaundinya, who assumed his new position effective September 25, 2017, ...
Aug 30, 2017
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it plans to provide a corporate overview, including an update on its collaboration with CSL for the development of M230, at the 2017 We...
Aug 2, 2017
$10M milestone payment from Sandoz earned for the second anniversary of Glatopa® 20 mg as the sole FDA-approved generic on the market for patients with relapsing forms of multiple sclerosis  Ended second quarter with a strong cash position of $457M  CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasd...
Jul 21, 2017
CAMBRIDGE, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company's U.S. Patent No. 7,575,886, covering methods for the manufacturing of generic LOVENOX® (Enoxaparin Sod...
Jul 19, 2017
CAMBRIDGE, Mass., July 19, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2017 before the U.S. financial markets open on Wednesday, August 2, 2017.    M...
Jun 7, 2017
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory submissions for marketing approval for M923, its ...
Jun 1, 2017
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Senior Vice President, Development. "Santiago's deep under...
1
...
NextLast
= add release to Briefcase